Interleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemia (Journal article)

Mavridis, A. K./ Tsiara, S./ Makis, A./ Chaidos, A./ Christou, L./ Seferiadis, K./ Bourantas, K. L.


Full metadata record
DC FieldValueLanguage
dc.contributor.authorMavridis, A. K.en
dc.contributor.authorTsiara, S.en
dc.contributor.authorMakis, A.en
dc.contributor.authorChaidos, A.en
dc.contributor.authorChristou, L.en
dc.contributor.authorSeferiadis, K.en
dc.contributor.authorBourantas, K. L.en
dc.date.accessioned2015-11-24T19:09:26Z-
dc.date.available2015-11-24T19:09:26Z-
dc.identifier.issn0392-9078-
dc.identifier.urihttp://olympias.lib.uoi.gr/jspui/handle/123456789/20703-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectInterleukins/*blooden
dc.subjectLeukemia, Lymphocytic, Chronic, B-Cell/*blood/diagnosis/metabolismen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPrognosisen
dc.subjectTumor Markers, Biological/*blooden
dc.subjectTumor Necrosis Factor-alpha/*metabolismen
dc.subjectbeta 2-Microglobulin/*metabolismen
dc.titleInterleukins, TNF-alpha and beta-2M in patients with B cell chronic lymphocytic leukemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10089066-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1998-
heal.abstractIn order to investigate the possible existence of a prognostic factor for B cell chronic lymphocytic leukemia (B-CLL), we determined the serum levels of TNF-alpha, IL-1a, IL-1b, IL-2, sIL-2R, IL-6, IL-10 and beta-2M in 20 patients. We observed significant changes in sIL-2R and beta-2M levels, whereas in all stages of disease, TNF-alpha and other interleukins exhibited only mild changes. An excellent correlation between sIL-2R and beta-2M levels and disease activity wes reported. Patients with aggressive disease (Rai stages III and IV and Richter's syndrome) had increased levels. Patients who responded to therapy and with improved clinical status had decreased sIL-2R and beta-2M levels. However, patients with progressive disease and no response to therapy were associated with increased levels of sIL-2R and beta-2M. In conclusions, as serum levels of sIL-2R and beta-2M are increased in the aggressive stages of B-CLL, they may be used as reliable markers for monitoring B-CLL activity, showing response to treatment and early relapse and/or disease progression.en
heal.journalNameJ Exp Clin Cancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/20703
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.